Hybrid pancreatic tissue substitute consisting of recombinant insulin-secreting cells and glucose-responsive material

Biotechnology and Bioengineering
S-Y ChengAthanassios Sambanis

Abstract

Insulin-dependent diabetes is a serious pathological condition, currently treated by blood glucose monitoring and daily insulin injections, which, however, do not prevent long-term complications. A tissue-engineered pancreatic substitute has the potential to provide a more physiologic, less invasive, and potentially less costly treatment of the disease. A major issue in developing such a substitute is the cells being used. Nonpancreatic cells, retrieved from the same patient and genetically engineered to secrete insulin constitutively or with some glucose responsiveness, offer the significant advantages of being immune-acceptable and relaxing the tissue availability limitations, which exist with islets from cadaveric donors. These cells, however, do not have insulin secretion dynamics appropriate for restoration of euglycemia in higher animals and, eventually, humans. In this study, we present the concept of a hybrid pancreatic substitute consisting of such cells sequestered in a material exhibiting glucose-dependent changes of its permeability to insulin. A Concanavalin A-glycogen material sandwiched between two polycarbonate membranes and exhibiting glucose-dependent sol-gel transformations was used. Rates of insulin transpor...Continue Reading

References

Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S EfratS Baekkeskov
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·F Fischel-GhodsianR Langer
Nov 1, 1985·Journal of Biomedical Materials Research·J KostM Singh
Jan 1, 1994·Journal of Biomaterials Science. Polymer Edition·K NakamaeA S Hoffman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Dec 1, 1999·The Journal of Pharmacy and Pharmacology·S TannaG Adams
Mar 1, 2000·Gene Therapy·P M ThuléL S Phillips
Apr 25, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·K PodualN A Peppas
Nov 18, 2000·Gene Therapy·P M Thulé, J M Liu
May 5, 2001·Biomaterials·C StablerI Constantinidis
Jul 27, 2001·Best Practice & Research. Clinical Endocrinology & Metabolism·A M ShapiroJ R Lakey
Jul 28, 2001·Pharmaceutical Research·J J Kim, K Park
Dec 18, 2001·Advanced Drug Delivery Reviews·Y Qiu, K Park
Dec 26, 2001·Transplantation Proceedings·A M ShapiroJ R Lakey
Jan 5, 2002·Advanced Drug Delivery Reviews·Akihiko Kikuchi, Teruo Okano
Nov 22, 2002·Journal of Drug Targeting·S TannaM J Taylor
Mar 1, 2003·Diabetes Care·Paul HoganUNKNOWN American Diabetes Association
Nov 1, 1982·Biotechnology and Bioengineering·C O Malikkides, R H Weiland

❮ Previous
Next ❯

Citations

Sep 10, 2011·Chemical Reviews·Qian WuZhefu Chen
Aug 24, 2006·Chembiochem : a European Journal of Chemical Biology·Margarita Sanchez DominguezAlain Belcourt
Jan 28, 2006·Biotechnology and Bioengineering·S-Y ChengA Sambanis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.